Clinical Efficacy of Bevacizumab Combined with Temozolomide in Treating Gliomas.

Objective: To examine the clinical efficacy of bevacizumab (BEV) combined with temozolomide (TMZ) as a treatment for patients with recurrent malignant gliomas. Methods: 50 patients with recurrent malignant gliomas treated at our hospital between January 2019 and January 2022 were enrolled and randomized to the control group and combine group using a random table method, with 25 cases in each group. The control group received TMZ and the combine group received BEV plus TMZ. The disease control rate (DCR), the quality-of-life score before and after treatment, and the median 6-month progression-free survival (PFS) rate as well as adverse reactions were recorded and compared. Results: There was a significant difference in DCR between the combine group (80%) and the control group (52%) (χ2 = 5.556, P = .018). In each of the quality-of-life scales, the scores of the combine group were significantly greater than those of the control group after treatment, and the difference was statistically significant (P < .05). In the control group, the median PFS was 16.2 weeks, and the six-month PFS was 19.8%. However, in the combine group, the median PFS was 21.9 weeks, and the six-month PFS was 43.1% (P < .05). Comparing the two groups, the rate of adverse reactions in the control group was significantly higher (44.0% vs 12.0%) (χ2 = 6.349, P = .012). Conclusion: BEV plus TMZ is remarkable in the treatment of patients with recurrent malignant gliomas. The combination treatment improves the DCR and PFS of patients and their quality of life, and does not increase adverse reactions, making it a promising approach that deserves widespread promotion and clinical application.

The Effect of Predictive Nursing Care for the Treatment of Senile Cerebral Tumors Treated by Craniotomy.

Objective: The current study aimed to analyze the postoperative intracranial infection in patients with senile cerebral tumors treated by craniotomy. Methods: This retrospective study included 116 patients with senile cranial tumors admitted and treated in our Hospital from January 2019 to January 2021. The patients were assigned to an observation group and a conventional group, by different nursing interventions, with 58 patients in each. Patients in both groups were treated with craniotomy, in which patients in the conventional group were given routine nursing. In contrast, patients in the observation group were provided with predictive nursing interventions. Predictive nursing interventions encompass personalized care plans, early identification of infection risk factors, and tailored prophylactic measures. A comparative analysis of the nursing intervention effect, self-management of the patients, and impact on the physical and mental health of the patients was performed between the two groups, with statistical significance set at P < .05. The Short Form Health Survey (SF-36) is a widely used and well-validated questionnaire designed to measure health-related quality of life and is adopted in this study to assess the quality of life of patients. Results: The number of intracranial infection cases in the observation group (4) was significantly less than in the conventional group (14), and the incidence of intracranial infection in the observation group (6.90%) was significantly reduced than in the conventional group (24.14%) (P < .05). Moreover, the effective rate of patients in the observation group (96.55%) was significantly higher than that in the conventional group (77.59%) (P < .05). The quality of life of patients in both groups improved, and the SF-36 score of patients in the observation group (70.25±7.18) was significantly higher than that of the conventional group (60.18±5.54) (P < .05). The total satisfaction of patients in the observation group (98.28%) was significantly higher than that of the conventional group (82.76%) (P < .05). Predictive nursing interventions minimize the incidence of postoperative complications, particularly intracranial infections, leading to improved treatment outcomes, enhanced quality of life, and increased patient satisfaction. Conclusion: The provision of predictive nursing care to patients with senile cranial tumors treated with craniotomy can effectively reduce the incidence of postoperative intracranial infection, and the nursing effect is better for patients with or without intracranial infection, which can significantly contribute to the quality of life quality improvement and effectively enhance patients' satisfaction. Further research is imperative to evaluate and promote the practice as a significant toolkit in clinical practice. Future investigations should focus on the enduring impact of predictive nursing interventions in senile cerebral tumor patients post-craniotomy, unraveling sustained benefits over an extended period. The study's findings underscore the potential for transformative nursing practices in craniotomy for senile cranial tumors, advocating for the integration of predictive nursing interventions to enhance patient safety, satisfaction, and overall well-being.

Altered T-cell receptor ß repertoire in adults with SARS CoV-2 inactivated vaccine of BBIBP-CorV.

OBJECTIVE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the prolonged and widespread epidemic of coronavirus disease 2019 (COVID-19). The inactivated BBIBP-CorV vaccine has shown safety, efficacy and immunogenicity against COVID-19 in in-vitro studies and clinical trials. However, the characteristics changes of the TCRß repertoire in patients receiving BBIBP-CorV remain unclear. METHODS: TCRß repertoire difference were analyzed between 54 uninfected subjects who received a third dose of the enhanced BBIBP-CorV vaccine and the 16 healthy donors who did not receive the vaccine and 44 COVID-19 patients with different courses of disease (asymptomatic, symptomatic and convalescent). Furthermore, antibody response, anti-inflammatory and pro-inflammatory cytokines also were examined. RESULTS: We found that the third dose inactivated coronavirus vaccine induced widespread changes including the increased TCRß repertoire diversity, a much shorter CDR3 length and high usage of V-J genes segments. Meanwhile, the vaccine-responding clones were also predicted. The results of the antibody response showed that 90.7 % of the vaccinated individuals were positive for NAb seroconversion and 88.9 % for IgG antibody about 60 days after the third dose. The concentration of IL-2 increased significantly compared to baseline inoculation. CONCLUSION: Altered TCRß repertoire in adults with SARS CoV-2 inactivated vaccine of BBIBP-CorV clarified the specific immunity induced by inactivated vaccines. Our research provides insights into the adaptive immune response induced by the new inactivated SARS-CoV-2 vaccine and strengthens the development of immunotherapy.

LncRNA MAFG-AS1 deregulated in breast cancer affects autophagy and progression of breast cancer by interacting with miR-3612 and FKBP4 invitro.

PURPOSE: We aimed to explore the function and competing endogenous RNA (ceRNA) pathway of MAFG-AS1 in breast cancer. METHODS: qRT-PCR assay identified the expression of MAFG-AS1, miR-3612 and FKBP4. We used Western blot analysis to test the autophagy related protein levels in breast cancer cells. Functional assays such as Cell Counting Kit-8 (CCK8) assay, BrdU proliferation assay, Caspase-3 activity detection were used to identify the function of MAFG-AS1, miR-3612 and FKBP4 in breast cancer cells. Mechanism assays were used to verify the interacting relationship among MAFG-AS1, miR-3612 and FKBP4, including RNA pull down assay, RNA immunoprecipitation (RIP) assay and luciferase reporter assay. RESULTS: MAFG-AS1 and FKBP4 were both up-regulated in breast cancer tissues. MAFG-AS1 could function as an oncogene in breast cancer to activate cell proliferation, and inhibit cell apoptosis and autophagy. Meanwhile, MAFG-AS1 could sponge miR-3612 to elevate the expression of FKBP4. Besides, FKBP4 could activate the cell proliferation and inhibit cell apoptosis and autophagy, which could relieve the inhibitory effect of miR-3612 on breast cancer cells. CONCLUSION: MAFG-AS1 could activate breast cancer progression via modulating miR-3612/FKBP4 axis in vitro.